Centrovet
Date: Nov 2012
Client: Centrovet
Counterparty: Virbac
Industry: Healthcare
Amount: Undisclosed amount
Transaction:
Landmark Alantra advised the shareholders of Centrovet, the leading Chilean laboratory of veterinary vaccines and pharmaceuticals, in the structuring and execution of a strategic partnership and joint venture with the French animal health company, Virbac S.A.
Nov 2012
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_francia.jpg?width=27&height=18&name=bandera_francia.jpg)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/centrovet2.jpg?width=130&height=48&name=centrovet2.jpg)
on the sale of 51% of the shares to
![](https://landmark-cap.com/hs-fs/hubfs/virbac2.jpg?width=130&height=48&name=virbac2.jpg)
Undisclosed amount
Similar transactions
Nov 2021
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_francia.jpg?width=27&height=18&name=bandera_francia.jpg)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/centrovet.png?width=130&height=48&name=centrovet.png)
on the sale of 34% of the shares to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/virbac.jpg?width=130&height=48&name=virbac.jpg)
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más